Form 4: MoonLake CFO Executes Planned Share Sale

MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 2,426 shares of Class A common stock via a 10b5-1 trading plan.

Summary

• Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, sold 2,426 Class A ordinary shares.
• The transaction occurred on April 14, 2026, at a weighted average price of $19.56 per share.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on December 10, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 1,186,084 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small fraction of the executive's total equity stake.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 plan, indicating the transaction was not based on non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term price appreciation, though this was a planned divestment.

Risks

• Market volatility affecting the share price of MoonLake Immunotherapeutics.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market sentiment regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate governance practice for executives to manage personal liquidity and is generally viewed as neutral by the investment community.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid allegations of insider trading.
• The volume of shares sold represents a negligible portion of the CFO's total holdings, which is consistent with standard wealth diversification practices.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

MoonLake Immunotherapeutics, MLTX, Insider Trading, Form 4, CFO, Equity Sale